Amylyx Pharmaceuticals, Inc.
AMLXNasdaq
$17.75
↑ +4.3%Jul 17 close · end-of-day
Price
1Y↑ +110.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.0B
Enterprise Value
$1.7B
P/E
—
P/S
—
P/B
7.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$150.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-54.9%
ROIC
—
Debt / Equity
—
Net Cash
$279.8M
Return 1Y
+114.4%
Company profile
Amylyx Pharmaceuticals, Inc. develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid.
- CEO
- Joshua B. Cohen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 200
- Headquarters
- Massachusetts
- Website
- amylyx.com
Management & directors
- Mazzariello GinaChief Legal Officer
- Bedrosian Camille LChief Medical Officer
- Cohen Joshua BCo-Chief Executive Officer
- Frates James MChief Financial Officer
- Klee Justin B.Co-Chief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
AMLX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.37↓ -11.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $285,000.00 | $22.2M | $380.8M | $87.4M | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$82.7M | -$201.3M | $38.8M | -$314.7M | -$153.3M |
| Net income | -$87.9M | -$198.4M | $49.3M | -$301.7M | -$144.7M |
| Diluted EPS | -$13.35 | -$3.39 | $0.70 | -$4.43 | -$1.53 |
| Operating cash flow | -$74.8M | -$179.9M | $11.9M | -$167.6M | -$123.3M |
| Free cash flow | -$75.2M | -$182.4M | $10.7M | -$167.8M | -$123.5M |
| Gross margin | — | — | — | — | — |
| Operating margin | -29013.3% | -905.7% | 10.2% | -360.2% | — |
| Net margin | -30853.0% | -892.4% | 12.9% | -345.4% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -$1.0M | $416,000.00 | -$665,000.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$76.3M | -$75.7M | -$40.7M | -$37.8M | -$42.9M | -$36.0M | -$36.6M | -$43.8M |
| Net income | -$72.7M | -$72.7M | -$37.5M | -$35.9M | -$41.4M | -$34.4M | -$33.0M | -$41.3M |
| Diluted EPS | -$1.07 | -$1.07 | -$0.54 | -$0.42 | -$0.46 | -$0.37 | -$0.28 | -$0.37 |
| Operating cash flow | -$66.6M | -$41.6M | -$59.0M | -$39.8M | -$25.2M | -$30.4M | -$27.9M | -$36.9M |
| Free cash flow | -$66.7M | -$41.6M | -$59.0M | -$39.8M | -$25.3M | -$30.4M | -$28.0M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 7457.1% | -18187.7% | 6113.4% | — | — | — | — | — |
| Net margin | 7106.5% | -17476.9% | 5646.0% | — | — | — | — | — |
Company news
Jun 10, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-10 | Mazzariello Gina· Chief Legal Officer | Sale | 15,000 | $17.61 | $264,121.50 | filing |
| 2026-07-09 | Mazzariello Gina· Chief Legal Officer | Sale | 15,000 | $18.32 | $274,746.00 | filing |
| 2026-05-21 | Firestone Karen | Buy | 3,800 | $13.51 | $51,338.00 | filing |
| 2026-03-05 | FRATES JAMES M· Chief Financial Officer | Award | 95,990 | $0.00 | $0.00 | filing |
| 2026-03-05 | Bedrosian Camille L· Chief Medical Officer | Award | 95,990 | $0.00 | $0.00 | filing |
| 2026-03-05 | Klee Justin B.· Co-Chief Executive Officer | Award | 248,865 | $0.00 | $0.00 | filing |
| 2026-03-05 | Cohen Joshua B· Co-Chief Executive Officer | Award | 248,865 | $0.00 | $0.00 | filing |
| 2026-03-05 | Mazzariello Gina· Chief Legal Officer | Award | 74,660 | $0.00 | $0.00 | filing |
| 2026-03-02 | Cohen Joshua B· Co-Chief Executive Officer | Sale | 29,282 | $14.48 | $424,120.49 | filing |
| 2026-03-02 | Klee Justin B.· Co-Chief Executive Officer | Sale | 29,282 | $14.47 | $423,760.32 | filing |
| 2026-03-02 | FRATES JAMES M· Chief Financial Officer | Sale | 7,909 | $14.52 | $114,851.33 | filing |
| 2026-03-02 | Mazzariello Gina· Chief Legal Officer | Sale | 6,844 | $14.52 | $99,378.30 | filing |
| 2026-03-02 | Bedrosian Camille L· Chief Medical Officer | Sale | 6,461 | $14.58 | $94,205.26 | filing |
| 2026-02-23 | Mazzariello Gina· Chief Legal Officer | Sale | 3,419 | $14.14 | $48,352.18 | filing |
| 2026-02-02 | Klee Justin B.· Co-Chief Executive Officer | Sale | 15,500 | $14.69 | $227,617.50 | filing |
| 2026-02-02 | Cohen Joshua B· Co-Chief Executive Officer | Sale | 15,500 | $14.68 | $227,592.70 | filing |
| 2026-02-02 | FRATES JAMES M· Chief Financial Officer | Sale | 3,557 | $14.65 | $52,096.89 | filing |
| 2026-02-02 | Mazzariello Gina· Chief Legal Officer | Sale | 3,448 | $14.65 | $50,515.61 | filing |
| 2026-01-16 | Klee Justin B.· Co-Chief Executive Officer | Sale | 1,995 | $13.89 | $27,701.17 | filing |
| 2026-01-16 | Cohen Joshua B· Co-Chief Executive Officer | Sale | 1,974 | $13.83 | $27,299.04 | filing |
| 2026-01-16 | Klee Justin B.· Co-Chief Executive Officer | Option exercise | 2,847 | $7.57 | $21,551.79 | filing |
| 2026-01-16 | Cohen Joshua B· Co-Chief Executive Officer | Option exercise | 2,818 | $7.57 | $21,332.26 | filing |
| 2026-01-15 | Cohen Joshua B· Co-Chief Executive Officer | Sale | 136,193 | $13.59 | $1.9M | filing |
| 2026-01-15 | Klee Justin B.· Co-Chief Executive Officer | Sale | 136,193 | $13.58 | $1.8M | filing |
| 2026-01-15 | Cohen Joshua B· Co-Chief Executive Officer | Option exercise | 197,182 | $7.57 | $1.5M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.